Mustang Bio announces scientific presentations on MB-101 (IL13R? 2? Targeted CAR T cells) at upcoming virtual conferences

0

WORCESTER, Mass.Mustang Bio, Inc. (‘Mustang’) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential treatments for hematologic cancers, solid tumors and genetic diseases rare, announced that Christine Brun, Ph.D., deputy director, T cell therapeutics research laboratory and The Heritage Provider Network Professor in Immunotherapy, will present updated phase 1 clinical data regarding MB-101 (IL13R? 2? CAR T-targeted cells) at two upcoming scientific conferences in October 2021.

The details of the virtual presentations are as follows:

First Annual CNS Clinical Trials Conference, co-sponsored by the Neuro-Oncology Society and American Society of Clinical Oncology

Title: CAR T cells in primary brain tumors

Session: Session 3: Immunotherapy – Hype and Hope

Date and time: Friday, October 1, 2021 To 2:30 p.m. ET

American Association for Cancer Research Special Virtual Conference: Brain cancer

Title: Advancing CAR T Cell Therapy for Glioblastoma

Session: Plenary session 2: New therapeutics

Date and time: Monday, October 25, 2021 To 1:15 p.m. ET

Mustang is collaborating with City of Hope on several chimeric antigen receptor T cell clinical trials, including the MB? 101 (IL13R? 2? CAR T cell targeted) clinical trials for brain cancer. Additional information on clinical brain cancer trials can be found at clinicaltrials.gov using the identifiers NCT04661384, NCT02208362 and NCT04003649.

About MB? 101 (IL13R? 2? Targeted CAR T cells)

IL13R? 2 is an attractive target for CAR T therapy because it has limited expression in normal tissues but is overexpressed on the surface of the majority of malignant glioma cells, including glioblastoma multiforme, ependymoma, and medulloblastoma. CAR T cells are engineered to express a membrane-bound IL-13 receptor ligand (IL-13) incorporating a unique point mutation that provides high affinity for IL13R-2 and reduces binding to IL13R-1 to reduce IL13R-1 binding. targeting healthy tissue. Mustang develops MB? 101 as an optimized CAR T product incorporating improvements in CAR design and T cell engineering to improve antitumor potency and T cell persistence. MB? 101 includes an optimized CAR for the second hinge generation containing mutations in the IgG4 linker to reduce off-target Fc interactions, the costimulatory signaling domain 4-1BB (CD137) for enhanced CAR T cell persistence and the extracellular domain of CD19 as a selection / safety marker. To further improve persistence, central memory T cells are enriched and genetically engineered using a manufacturing process that limits ex vivo expansion to reduce T cell depletion and maintain a memory T cell phenotype. .

On Mustang Bio

Mustang Bio, Inc. is a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapy into potential treatments for hematologic cancers, solid tumors and rare genetic diseases. Mustang aims to acquire rights to these technologies by licensing or acquiring an interest, to fund research and development, and to license or bring the technologies to market. Mustang has partnered with leading medical institutions to advance the development of CAR T therapies for several cancers, as well as lentiviral gene therapy for severe X-linked combined immunodeficiency. Mustang is registered under the Securities Exchange Act of 1934, as amended, and files periodic reports with the United States Securities Commission (‘SECOND‘). Mustang was founded by Forteresse Biotech, Inc. (NASDAQ: FBIO). For more information, visit www.mustangbio.com.

Forward-looking statements

This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Such statements include, without limitation, any statement relating to our growth strategy and product development programs and any other statements which are not historical facts. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could adversely affect our business, results of operations, financial condition and the value of our shares. Factors that could cause actual results to differ materially from those currently anticipated include: risks related to our growth strategy; our ability to secure, execute and maintain funding and strategic agreements and relationships; risks related to the results of research and development activities; risks associated with the timing of the initiation and completion of clinical trials; uncertainties relating to preclinical and clinical trials; our dependence on third party suppliers; our ability to attract, integrate and retain key personnel; the initial stage of products under development; our need for substantial additional funds; government regulations; patent and intellectual property issues; competetion; as well as other risks described in our SECOND deposits. We expressly disclaim any obligation or commitment to publicly release any update or revision to any forward-looking statement contained herein to reflect any change in our expectations or any change in the events, conditions or circumstances upon which such statement is based, except as required by law, and we claim safe harbor protection for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.

Contact:

Jaclyn Jaffe

Bill Begien

Mustang Bio, Inc.

T: (781) 652-4500

E: [email protected]

Investor

Daniel Ferry

LifeSci Advisors, LLC

Phone. : (617) 430-7576

E: [email protected]

Media

Tony Plohoros

6 degrees

T: (908) 591-2839

E: [email protected]


Source link

Leave A Reply

Your email address will not be published.